**Second-Look Ultrasound Using Shear-Wave Elastography in MRI-Suspected Locoregional Recurrence of Breast Carcinoma**

**ZUSAMMENFASSUNG**


**ABSTRACT**

**Purpose** | To investigate if second-look US using shear-wave elastography (SWE) can help to differentiate between benign and malignant changes in the postoperative breast after surgical treatment of breast carcinoma.

**Materials and Methods** | SWE and related sonoographic features were reviewed in 90 female patients with a history of surgical treatment of breast carcinoma and a suspicious lesion detected on a follow-up MRI scan. A single experienced radiologist performed all second-look US exams with SWE measurements placing a circular region of interest measuring 2 mm in diameter over the stiffest part of the lesion. Tissue samples for histopathological analysis were obtained during the same US examination via core-needle biopsy.

**Results** | Out of 90 lesions, 39 were proven malignant on histopathological analysis. 50% of malignant lesions had \( E_{\text{max}} \) values ranging from 128 to 199 kPa, and 50% of benign lesions had \( E_{\text{max}} \) values ranging from 65 to 169 kPa. The cut-off value of 171.2 kPa for \( E_{\text{max}} \) shows a sensitivity of 59% and specificity of 78.4% for carcinoma recurrence, area under the curve 0.706 (CI95% 0.6 – 0.81), \( P < 0.001 \). In univariate logistic models, restricted diffusion and stiffness on SWE, \( E_{\text{max}} > 171.2 \) kPa, were shown as significant recurrence predictors. In the multivariate model, restricted diffusion remains significant independent recurrence predictor. With a recurrence prevalence of 43%, the test sensitivity is 95% (CI95% 81 – 99%) and the specificity is 75% (CI95% 60 – 85%).

**Conclusion** | Stiffer lesions should be considered suspicious on second-look US in the postoperative breast and SWE can be a helpful tool in identifying malignant lesions, especially if this is related to restricted diffusion on MRI exam. Lesion stiffness, however, should not be considered as an independent predictor of lesion malignancy in the postoperative breast, because of benign changes that can appear stiff on SWE, as well as carcinoma recurrences that may appear soft.
Introduction

Although primary breast carcinoma is still the most common malignancy in women, management of this disease has changed in the last two decades, with the multidisciplinary approach leading to a decrease in local recurrence (LR) incidence rates [1, 2]. Reported rates vary depending on the advancement of the primary tumor as well as administration of adjuvant therapy: 3–5% 10-year incidence rate is reported for early breast carcinoma with adjuvant radiotherapy, while 5-year incidence rates of around 35% were reported in patients who did not receive adjuvant radiotherapy [3, 4]. The reported 10-year incidence of LR for patients who underwent mastectomy was 3–8% [2, 5]. Although LR incidence rates are decreasing, postoperative changes in the breast after oncoplastic surgery as well as changes due to adjuvant radiation or systemic therapy can present a challenge in differentiating carcinoma recurrence from iatrogenic breast changes, both on physical exam [6, 7] and imaging methods [8–10]. Although magnetic resonance imaging (MRI) has high sensitivity and specificity in LR detection, annual screening after breast-conserving surgery (BCS) is not routinely recommended [11]. However, a recent survey by the European Society of Breast Imaging (EUSOB) has shown that approximately 45% of participants use MRI for the detection of LR after BCS [12]. This can lead to an increased number of false-positive findings, due to postoperative changes which may result in post-contrast enhancement on T1 sequences, such as early scarring, seroma, and fat necrosis [13, 14]. Suspicious lesions detected by breast MRI are commonly assessed and biopsied under guidance of a targeted ultrasound (US) examination (“second-look” US) [15, 16]. However, US is an operator-dependent method and lesion detection rates for second-look US vary between 22.6% and 82.1% [16]. Sonoelastography is a relatively new ultrasonographic method, which has been proven helpful in the detection and differentiation of benign and malignant breast lesions [17, 18]. This study aims to investigate whether second-look US using shear-wave elastography (SWE) can help differentiate between benign and malignant changes in the postoperative breast.

Materials and Methods

The design of this single-center study was prospective. This study was approved by our hospital’s ethics committee and was performed according to the standards of good clinical practice. Written informed consent from the patients was waived, since SWE was performed during the routine second-look US examination after breast MRI. SWE and related sonographic features were reviewed in 90 female patients (29–83 years old, mean age: 57 years, median: 58 years). The inclusion criteria included adult female patients with a history of surgically treated breast carcinoma, who were scheduled for follow-up MRI, and a suspicious lesion requiring histopathological assessment detected on a follow-up MRI scan. The exclusion criteria included a history of previously detected breast carcinoma recurrence. The MRI scans were performed in an eight-year period (2011–2018) in our department. MRI scans were performed on two 1.5 T MRI scanners (Avanto, Siemens, Germany and Ingenia, Philips, Netherlands), using dedicated breast coils and a standard multiparametric protocol including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE)-MRI. Signal intensity (SI) on T2WI, signs of restricted diffusion on DWI and apparent diffusion coefficient (ADC) map as well as enhancement patterns and kinetics were observed. The lesion size and type of margins were also noted. If multiple lesions were present, the index lesion was chosen depending on the most suspicious MRI features (e.g. irregular mass with irregular edges showing contrast uptake, or new enhancing lesion not present on earlier MRI exams, or higher intensity of enhancement in a previous lesion) and size of the lesion (largest lesion). All patients underwent the SWE examination on the same state-of-the-art ultrasound scanner Aixplorer (Supersonic Imagine, Aix en Provence, France), with the same linear high-frequency 4–15 MHz transducer. All US examinations were performed by a single experienced breast radiologist with more than 25 years of breast US experience. The images were taken immediately prior to US-guided core biopsy and were stored on the device. The stiffness of the lesion expressed in kilopascals was measured using the built-in quantification region of interest (ROI) of the system (Q-Box). An ROI size of 2 mm was used in all measurements, placed by the investigator over the lesion (largest lesion). All patients underwent the SWE examination during the routine second-look US examination. The exclusion criteria included a history of previously detected breast carcinoma recurrence. The MRI scans were performed in an eight-year period (2011–2018) in our department. MRI scans were performed on two 1.5 T MRI scanners (Avanto, Siemens, Germany and Ingenia, Philips, Netherlands), using dedicated breast coils and a standard multiparametric protocol including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE)-MRI. Signal intensity (SI) on T2WI, signs of restricted diffusion on DWI and apparent diffusion coefficient (ADC) map as well as enhancement patterns and kinetics were observed. The lesion size and type of margins were also noted. If multiple lesions were present, the index lesion was chosen depending on the most suspicious MRI features (e.g. irregular mass with irregular edges showing contrast uptake, or new enhancing lesion not present on earlier MRI exams, or higher intensity of enhancement in a previous lesion) and size of the lesion (largest lesion). All patients underwent the SWE examination on the same state-of-the-art ultrasound scanner Aixplorer (Supersonic Imagine, Aix en Provence, France), with the same linear high-frequency 4–15 MHz transducer. All US examinations were performed by a single experienced breast radiologist with more than 25 years of breast US experience. The images were taken immediately prior to US-guided core biopsy and were stored on the device. The stiffness of the lesion expressed in kilopascals was measured using the built-in quantification region of interest (ROI) of the system (Q-Box). An ROI size of 2 mm was used in all measurements, placed by the investigator over the

Materials and Methods

The design of this single-center study was prospective. This study was approved by our hospital’s ethics committee and was performed according to the standards of good clinical practice. Written informed consent from the patients was waived, since SWE was performed during the routine second-look US examination after breast MRI. SWE and related sonographic features were reviewed in 90 female patients (29–83 years old, mean age: 57 years, median: 58 years). The inclusion criteria included adult female patients with a history of surgically treated breast carcinoma, who were scheduled for follow-up MRI, and a suspicious lesion requiring histopathological assessment detected on a follow-up MRI scan. The exclusion criteria included a history of previously detected breast carcinoma recurrence. The MRI scans were performed in an eight-year period (2011–2018) in our department. MRI scans were performed on two 1.5 T MRI scanners (Avanto, Siemens, Germany and Ingenia, Philips, Netherlands), using dedicated breast coils and a standard multiparametric protocol including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE)-MRI. Signal intensity (SI) on T2WI, signs of restricted diffusion on DWI and apparent diffusion coefficient (ADC) map as well as enhancement patterns and kinetics were observed. The lesion size and type of margins were also noted. If multiple lesions were present, the index lesion was chosen depending on the most suspicious MRI features (e.g. irregular mass with irregular edges showing contrast uptake, or new enhancing lesion not present on earlier MRI exams, or higher intensity of enhancement in a previous lesion) and size of the lesion (largest lesion). All patients underwent the SWE examination on the same state-of-the-art ultrasound scanner Aixplorer (Supersonic Imagine, Aix en Provence, France), with the same linear high-frequency 4–15 MHz transducer. All US examinations were performed by a single experienced breast radiologist with more than 25 years of breast US experience. The images were taken immediately prior to US-guided core biopsy and were stored on the device. The stiffness of the lesion expressed in kilopascals was measured using the built-in quantification region of interest (ROI) of the system (Q-Box). An ROI size of 2 mm was used in all measurements, placed by the investigator over the
stiffest part of the lesion, determined based on the color map generated by the scanner. The breast preset in the penetration mode was used for all measurements, with the highest stiffness set at ≥ 300 kPa. Quantitative SWE features were measured: mean (Elmean), maximum (Elmax), and minimum (Elmin) elasticity value of the stiffest portion of the lesion. US-guided core biopsy under local anesthesia was performed using a 14G needle and BARD MAGNUM Reusable Core Biopsy System (Bard biopsy, Arizona, USA) to obtain tissue samples for histopathological analysis.

Statistical analysis

The patients were divided into two groups based on histopathological findings (verified carcinoma recurrence and benign breast lesion). Normality of the distribution of quantitative variables (patient age, MRI lesion size and SWE measurements, months free from disease) was analyzed using the Kolmogorov Smirnov test. Distributions of quantitative variables were presented as median and Q1–Q3 range. Differences in the distribution of qualitative variables between the two groups were analyzed with the Mann-Whitney U-test and results were presented as adjusted z- and P-values. With the given sample size, the test had power 75 % to determine effect size d = 0.5.

The distribution of qualitative variables was presented in tables and differences in their distributions were analyzed with Pearson’s χ² or Fisher’s exact test. Pearson’s χ² test with df = 1 had power 81 % to determine effect size w = 0.5 whereas the power of the test with df = 2 was 72 %.

The diagnostic accuracy and optimal cut-off value for SWE measurements between the two groups were obtained based on the value of the area under the ROC curve.

Logistic regression models were constructed to investigate the predictive values of MRI (SI on T2WI, enhancement patterns and kinetic curves as well as restricted diffusion) and SWE parameters (Elmean, Elmax and Elmin) on histopathological findings (canceroma recurrence). All statistical analyses were performed using TIBCO Software Inc. (2018) Statistica (data analysis software system), version 13 (http://tibco.com).

Results

In 39 patients (43.3 %), breast carcinoma recurrence was proven by histopathological analysis of a tissue sample obtained by core biopsy. In 51 patient (56.7 %), scar tissue or another benign breast lesion was found. Statistical analyses (Mann-Whitney U-Test) revealed no difference between the two groups of patients regarding age, months free from disease and lesion size (Supplementary Table 1).

The type of breast surgery patients underwent showed no difference regarding carcinoma recurrence, Fisher’s exact test P = 0.547. (Supplementary Table 2).

Carcinoma recurrences more often appeared as T2-hypointense. Almost all (37 out of 39, or 94.9 %) recurrences showed restricted diffusion on DWI and ADC maps, compared to only 13 of 51 benign lesions (25.5 %). In carcinoma recurrence, two thirds of participants (26 of 39, or 66.7 %) had a washout kinetic curve. In case of benign lesions, 19 of 51 (37.3 %) had a washout kinetic curve, 21 (41.2 %) had a plateau kinetic curve and 11 (21.6 %) had a persistent kinetic curve (Supplementary Table 3).

Carcinoma recurrences in general showed higher stiffness values on SWE when compared to benign lesions (distribution of Elmax, Elmean and Elmin between groups is shown in Supplementary Table 4). While 50 % of Elmax values in malignant lesions ranged from 128 to 199 kPa. One carcinoma recurrence was very soft, measuring Elmax of only 32.7 kPa.

ROC curve analysis was applied to analyze the diagnostic accuracy of measurements and the optimal cut-off values for Elmax and Elmean values (Supplementary Fig. 1) between verified recurrence and benign lesion.

An Elmax value of 171.2 kPa shows a sensitivity of 59 % and a specificity of 78.4 % for carcinoma recurrence, area under the curve 0.706 (CI95 % 0.6–0.81), P = 0.001. An Elmean value of 148.5 kPa shows a sensitivity of 59 % and a specificity of 74.5 % for carcinoma recurrence, area under the curve 0.703 (CI95 % 0.59–0.81), P = 0.001.

Logistic regression models have shown that information about diffusion restriction obtained from MRI, exam, hypointensity, washout curve compared to persistent curve and SWE Elmax > 171.2 kPa can serve as individual predictors for lesion malignancy. In the multivariate model, restricted diffusion remains a significant independent predictor of carcinoma recurrence (Supplementary Table 5).

With a prevalence of carcinoma recurrence of 43 %, diffusion restriction has a sensitivity of 95 % (CI95 % 81–99 %) and a specificity of 75 % (CI95 % 60–85 %). The test is most valuable if the test result is negative. The probability of having disease if the test is positive is 74 % (CI95 % 64–82 %) and 5 % (CI95 % 2–17 %) if the test is negative.

Regarding SWE, for Elmax > 171.2 kPa, with a prevalence of carcinoma recurrence of 43 %, the test sensitivity is 59 % (CI95 % 42–74 %) and the specificity is 78 % (CI95 % 64–88 %). The probability of true recurrence is 68 % (CI95 % 54–79 %) in the case of positive test results and 29 % (CI94 % 21–37 %) in the case of negative test results.

With a prevalence of carcinoma recurrence of 43 %, T2-hypointensity showed sensitivity for malignancy of 62 % (CI95 % 45–76 %) and specificity of 63 % (CI95 % 48–76 %). The probability of true recurrence is 56 % (CI95 % 45–66 %) if the test result is positive and 32 % (CI95 % 23–42 %) in the case of a negative test result.

Discussion

SWE, unlike strain elastography, allows for quantification of lesion stiffness. Furthermore, it is highly reproducible for assessing elastographic features of breast masses within and across observers [17]. These were the main reasons for choosing SWE over strain elastography in our study. SWE is being widely used in clinical practice, especially in the characterization of breast lesions. However, evidence regarding the value of SWE in differentiating benign postoperative changes in the breast from local carcinoma recurrences is scarce. A PubMed search performed in October 2019 resulted in only one study that investigated the sensitivity and specificity of SWE in suspected recurrence of breast carcinoma.
This study included 29 patients with 32 masses and although it was shown that SWE can discriminate between benign and malignant lesions, it was not recommended to perform biopsies based on SWE results only.

Our study included a larger number of patients, but is still limited by the relatively small pool of patients with suspected recurrence of breast carcinoma. Our results also show increased stiffness of malignant lesions (Fig. 1) in comparison to benign postoperative changes (Fig. 2), but with a significant overlap of SWE parameters between the two groups, probably due to increased stiffness of fibrotic changes present in the postoperative breast (Fig. 3). In our study, the best-performing SWE parameter in diagnosing breast lesions was $E_{\text{max}}$, similar to evidence from earlier studies [17, 20–23]. Another parameter that could be useful is $E_{\text{ratio}}$ [21, 23–25], which requires comparison of lesion stiffness with the stiffness of fat tissue. Due to postoperative changes, it was not always possible to capture fat tissue in the Q-Box, so the authors decided to focus on measurements of lesions alone. The cut-off value of 171.2 kPa for $E_{\text{max}}$ is significantly higher than the cut-off values that are reported in studies on primary carcinomas, which range from 46.7 to 93.8 kPa (median: 79.25 kPa) [23], although it is not uncommon for malignant lesions to show $E_{\text{max}}$ values above 130 kPa [26–28]. It is known that tumor stiffness is related to tumor size and immunohistochemical profile [27, 29]. Our study included relatively small lesions (median diameter of malignant lesions was 16 mm), and stiffness probably resulted from intrinsic tumor properties rather than size. Most of malignant lesions in our study had $E_{\text{max}}$ values between 128 and 199 kPa. However, we also encountered a soft carcinoma recurrence, with an $E_{\text{max}}$ value of only 32.7 kPa (Fig. 4), possibly due to the small lesion size (8 mm in

[Fig. 1] A small, heterogeneous breast lesion occurring 14 years after breast segmentectomy. Lesion shows high stiffness on SWE, with $E_{\text{max}}$ value of 241.5 kPa. Histopathological analysis-proven locoregional recurrence of Luminal B Her2-negative carcinoma.

[Fig. 2] A surgical scar in the postoperative breast presented as an irregular, spiculated enhancing lesion on follow-up MRI. Second-look US with SWE shows that the lesion is in fact soft, while biopsy revealed scar tissue.

[Fig. 3] A hypoechic, irregular, spiculated breast lesion after breast-conserving surgery. The lesion showed post-contrast enhancement on MRI and high stiffness on SWE. Biopsy revealed scar tissue.

[Fig. 4] A small, hypoechic breast lesion after skin-and-nipple-sparing mastectomy and reconstruction using breast implant. While SWE showed very low $E_{\text{max}}$ values, biopsy revealed a carcinoma recurrence.
diameter) and/or histopathological properties of the tumor. This served as a good reminder of the diverse appearance of breast carcinomas on SWE. The sensitivity of Elmax with the proposed cut-off value was 59 % (CI95 % 42–74), while the specificity was 78 % (CI95 % 64–88).

Regarding MRI findings, two different MRI devices were used in the study, but both are state-of-the-art scanners with same MRI field strength (1.5 T) and the same protocols were used on both devices. Therefore, we believe this couldn’t cause any significant bias in our data. Results have shown that restricted diffusion on DWI and ADC map can serve as an individual predictor for lesion malignancy (▶ Fig. 5), with a sensitivity of 95 % (CI95 % 81–99) and specificity of 75 % (CI95 % 60–85). Restricted diffusion remains a significant independent predictor of carcinoma recurrence in the multivariate model. Other MRI parameters, including DCE variables, have shown a lower predictive value for carcinoma recurrence, which can be explained by the tendency of postoperative changes (that as a rule include fibrous healing and inflammation) to show washout enhancement pattern and irregular shape [8, 30]. On the other hand, the value of DWI in breast carcinoma detection has become more prominent in recent studies and this technique is now being incorporated into MRI breast protocols more often [31, 32]. Not only can it give information about lesion hypercellularity, but there are also some indications that DWI could be applicable for morphological assessment [33].

In conclusion, stiffer lesions should be considered suspicious on second-look US in the postoperative breast and SWE can be a helpful tool for identifying malignant lesions, especially if this is related to restricted diffusion on MRI exam. Lesion stiffness, however, should not be considered as an independent predictor of lesion malignancy in the postoperative breast, because of benign changes that can appear stiff on SWE, as well as carcinoma recurrences that may appear soft.

**Funding**

This work has been supported by Croatian Science Foundation under the project IP-2016-06-2997 “Sonoelastography and MRI in diagnosis and treatment of breast cancer”.

**Conflict of Interest**

The authors declare that they have no conflict of interest.

**References**
